Kenvue Inc. (NYSE:KVUE) Declares $0.20 Quarterly Dividend

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, April 25th, Zacks reports. Stockholders of record on Wednesday, May 8th will be given a dividend of 0.20 per share on Wednesday, May 22nd. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.24%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue has a dividend payout ratio of 64.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Kenvue to earn $1.25 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 64.0%.

Kenvue Stock Performance

NYSE:KVUE opened at $18.86 on Friday. The company’s 50 day moving average price is $19.84 and its 200-day moving average price is $20.13. Kenvue has a 52 week low of $17.82 and a 52 week high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. The business’s revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts predict that Kenvue will post 1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Royal Bank of Canada lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. JPMorgan Chase & Co. lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Finally, Sanford C. Bernstein began coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.